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1. Introduction
The status  of  the immune system plays a  major  role  tumor progression.  Lewis  Thomas
proposed the association between immune surveillance and tumor progression as early as
the 1950’s. He suggested that the adaptive immune system has evolved to detect changes
in the body’s own cell  surfaces due to damage or mutation.  T cells,  which specialize in
monitoring cell surfaces, usually in the context of MHC molecular presentation, carry out
this role; if a cell is deemed to be abnormal, it is destroyed before a mutant clone has time
to proliferate and progress. Thus, the development of cancer could be seen as a failure of
the immune system.
This chapter will discuss the ongoing interaction between the tumor development and the
immune system, a process that has been called immunoediting. We will focus on tumors
involving  the  central  nervous  system  in  both  adult  and  pediatric  settings—high  grade
gliomas  (WHO  grades  III  and  IV  tumors).  We  will  review  of  the  normal  mechanisms
employed by the immune system in combating tumor cells including cytotoxic T cells, Th1/
Th2 cells, Natural Killer (NK) cells, B cells, macrophages, and the complement system.
Furthermore, we will explore the topic of tumor-associated antigens (TAA) in brain tumors,
where  we  will  start  the  review  of  alternative  tactics  of  brain  tumor  treatments  using
immunotherapy. Although there have been relatively few successes in the field of immuno‐
therapy, we will review the recent developments in brain tumor immunotherapy research
and the different on-going clinical trials.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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2. The immune system
2.1. General defense mechanisms
The immune system is the backbone of the body’s defense against foreign invaders including
bacteria, fungi, parasites, and viruses. The ability of humans to resist infections is composed
of multiple systems working together, the first of which are the physical barriers of innate
immunity lining the human body and entry points—skin and mucous membranes. Those
physical barriers possess special properties that help fend off unwanted microorganisms
including the ability to regenerate and secretion of antibiotics—defensin and cathelicidin
families. However, under certain circumstances the physical barriers fail, allowing foreign
intruders to venture deep inside the body requiring the activation of the immune system.
The immune system is comprised of two major divisions: the innate and adaptive immune
systems. The innate system is not specific to a single pathogen, but is dependent on specific
group of proteins and cells to recognize conserved features of pathogens. The main compo‐
nents of the innate system include 1) physical epithelial barriers discussed above, 2) phagocytic
leukocytes, 3) dendritic cells, 4) natural killer (NK) cells, and 5) circulating plasma proteins.
Using toll-like receptors (TLRs), the innate system is able to recognize pathogen-associated
molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) and
respond within minutes. The adaptive immune system, on the other hand, is capable of
recognizing new antigens and forming memory cells. The adaptive immune is activated when
pathogens overcome the defenses of the innate system. Adaptive responses, however, are slow
to respond at initial exposure to a new pathogen since specific clones of B and T cells are not
yet activated. There are two types of adaptive immunity: humoral and cell-mediated immun‐
ity. Humoral immunity is mediated via antibodies secreted by B-lymphocytes whereas cell-
mediated immunity is carried out by T-lymphocytes.
2.2. Induction of immune responses to antigens
Consider a scenario where a pathogen bypasses the physical barriers of the innate immune
system. The pathogen is then recognized as foreign, taken up by professional antigen-
presenting cells (APCs) and delivered to the nearest lymph node via the lymphatic system
where T lymphocytes are activated. Alternatively, antigens can reach the lymph node by
passive drainage where they are taken up by macrophages and dendritic cells (DCs). The
antigens are then processed and presented to T-lymphocytes in association with MHC
molecules. The simultaneous binding of T-cell receptor (TCR) to major histocompatibility
complex (MHC) molecules and stimulation via APC’s co-stimulatory molecules initiates T-cell
activation. The T-lymphocyte may be a “helper T cell” that is now capable of aiding in
activating “killer T cells” (cytotoxic T-lymphocytes, CTLs) and B-lymphocytes.
2.3. Immune surveillance
Immune surveillance is the theory that the immune system evolved not only to protect the
body against foreign pathogens but also host cells that become tumorigenic. This idea,
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proposed in the 1950’s, was quite prescient given that self monitoring done by T-cells was not
discovered until 20 years later [1]. There is some evidence for this attractive notion: 1) Patients
with T-cell immunodeficiencies have a higher incidence of tumors, e.g. AIDS patients have a
higher incidence Burkitt’s lymphoma and Kaposi’s sarcoma; 2) Organ transplant patients
treated with immunosuppressive drugs had 25 to 100 fold increase in tumor incidence relative
to healthy controls; 3) Tumor-Infiltrating Lymphocytes (TILs) have been identified that are
capable of recognizing tumor-associated antigens. The most persuasive evidence, however,
comes from the chemically-induced sarcomas in RAG2-/-mice. RAG2 knockout mice fail to
produce mature B and T cells due to lack of recombinase enzymes that are necessary to generate
mature and functional antibodies and T-cell receptors [2]. Tumor cells induced in this knockout
strain could be transplanted to new knockout hosts with 100% take rate, whereas wild-type
mice of the same strain rejected 60% of the tumor challenges [3]. These experiments suggested
that the immune system plays an active role in defending the body against cancerous cells.
Additionally, this suggests that certain types of tumors or cells within a tumor may be strongly
immunogenic inciting an immune response, while other cells may be weakly immunogenic.
For instance, cells that are driven (eg, by heat stress) to be immunogenic are rejected by
immune-competent syngeneic hosts, but those cells will grow at the same rates as control
(unstressed) cells in immune-compromised (nu/nu) mice (Figure 1). We can then conclude that
Figure 1. Immune mechanisms in tumor growth control: Tumor cells rendered immunogenic (by heat shock) are reject‐
ed by immune competent hosts, but grow unrestricted in immune-compromised mice. In this experiment, heat-
shocked murine brain tumor cells became immunogenic (possibly due to the release of stress proteins) compared to
non-heat shocked cells and were rejected following injection into syngeneic, immune-competent hosts. However, in
immune-compromised mice (athymic nude mice, in this case, lacking T lymphocytes), heat shocked tumor cells grew
equally large tumors as the non-heat shocked cells, indicating that the heat stress did not compromise cell viability,
and that an intact immune system is required for rejection of the implanted tumors. Note differences in day of tumor
measurements and the differences in the tumor volume axes.
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the immune system of mice plays a role in determining the pro-or anti-immune phenotypes
of tumors that arise in mice, and possibly humans, a process termed immunoediting.
2.4. Immunoediting
The interaction between the immune system and tumor development has been termed
immunoediting. One can think of the role of the immune system in immunoediting as the
selective force on tumors, a process analogous to Darwinian selection. The process of immune
editing can result into 3 outcomes: 1) the tumor cells are successfully eliminated as seen in the
WT mice (Figure 1); 2) The tumor cells and lymphocytes exist in equilibrium; 3) Tumor cells
initiate several responses that result in the suppression of the immune system or avoidance of
immune effectors.
2.4.1. Tumor cell elimination
Compared to normal cells, tumor cells display a variety of metabolic abnormalities leading to
the expression of damage associated molecular patterns (DAMPs) [4], as well as the stress
expression of NK ligands such as MICA/B and ULBP families [5]. The expression of DAMPs
and other stress molecules leads to the activation of the innate immune system, which in turn
activates the adaptive immune system via APCs and cytokine release. The adaptive response
yields stimulated effector lymphocytes. The end result is macrophage and lymphocyte
infiltration of the tumor. If the abnormal clone is successfully eliminated, the process of
immunoediting ends here. If the abnormal clone persists, however, then it can exists in
equilibrium or grow beyond the control of the immune system [6].
2.4.2. Equilibrium
Another outcome to the infiltration of tumors by lymphocytes is incomplete eradication of the
tumor. In this scenario, the abnormal clone and lymphocytes exist in equilibrium where the
lymphocytes keep the tumor in check, but fail to entirely eradicate it, aided by regulatory T
cells (Tregs, a subset of lymphocytes with immune suppressive properties) [7]. This may result
in tumor dormancy (sometimes called “occult” cancers), but the mechanisms of this are poorly
understood [8, 9].
2.4.3. Escape
The third phase of the immunoediting paradigm is escape of the tumor from immune attacks.
This is often regarded as an “immune sculpting” phenomenon [10] that leads to immune
pressure selection and outgrowth of unrecognized tumor clones. In combination with the
aforementioned Tregs, the tumor may reach sufficient size that it can generate its own immune
suppressive microenvironment, leading to growth and metastases in the face of an ineffectual
immune response. In light of tumor selection and tumor-induced immune suppression, what
factors lead to immune recognition of tumors?
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3. Detection of neoplastic tissue
The immune system is generally very successful in eliminating viral infections and certain
virus-induced tumors due to the vast difference in structure between viral and self-antigens.
So, how are tumors lacking a viral etiology recognized and eliminated?
3.1. Tumor associated antigens
TAAs are antigens that are expressed by tumor cells and not readily found on corresponding
normal cells. TAA can be found on normal cells, but are usually overexpressed or abnormally
expressed on tumor cells. There are several types of TAAs: 1) viral gene products; 2) mutant
gene products; 3) normal gene products. Viral antigens are expressed in tumors caused by
viral infections: e.g. HTLV-1 and HTLV-2 viruses causing mycosis fungoides, human papil‐
loma virus (HPV) in cervical cancer, Epstein-Barr virus (EBV) in Burkitt’s lymphoma, and
hepatitis B and C viruses (HBV, HCV) in hepatocellular carcinomas [11]. Mutant gene products
are often found in transformed cells that may be part of the transformation process, or caused
by physical and chemical carcinogens resulting in mutated proteins. Mutant gene products
vary from one patient to the other and represent tumor-specific antigens (TSA). It has been
estimated that tumors may have scores to hundreds of mutations that lead to recognizable
epitopes [12].
Normal gene products are found on corresponding normal cells, but may overexpressed by
tumors, such as epidermal growth factor family members (eg, HER2/Neu [13]). Others may
be inappropriately expressed outside developmental or differential stages, such as oncofetal
antigens and differentiation antigens. Differentiation antigens are lineage specific antigens that
are usually overexpressed e.g. prostate-specific antigen (PSA) or the melanoma antigens
MART1, TRP1, and tyrosinase. Oncofetal antigens are normally expressed in fetal tissue but
not adult tissue. Perhaps the most familiar oncofetal antigen is the carcinoembryonic antigen
(CEA) found in patients with colon carcinoma, amongst others. A review describing a
comprehensive database for tumor antigens may be found here [14].
3.2. Effectors of the immune system
How does the immune system manage to eliminate tumors once an abnormal clone is
recognized? Perhaps the most important cell in the topic of anti-tumor resistance is the
CD8+cytotoxic T-lymphocyte (CTL).
CTLs are capable of recognizing TAAs presented on MHC class I molecules, which are present
on the surface of most cells in humans. Following activation, CD8+CTLs undergo clonal
expansion and migrate towards the tumor. CTLs then eliminate abnormal clones by inducing
apoptosis through perforin or Fas-mediated pathways. Additionally, CTLs secrete IFN γ upon
engagement of their TCR, attracting macrophages. CTLs, however, can be inactivated upon
arrival to tumor site as identified in melanoma patients [15, 16]. As a component of normal
regulatory mechanisms, CTLs carry a surface marker, PD-1, that when engaged inactivates the
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CTL. Many tumor types, however, up regulate PD-1 ligand (PD-L1 or PD-L2) in order to
suppress and evade CTL activity.
Another notable cell belongs to a subset of CD4+T-lymphocytes, the type 1 T-helper cell (Th1).
Th1 cells play a major role in recognition of antigens, production of lymphokines, activation
of CD8+CTLs, and attracting M1 macrophages. Th1 cells then could play an important role in
development of cancer vaccines [17].
Natural Killer (NK) cells are part of the immune system and are also known as large granular
lymphocytes (LGLs). Being part of the immune system, NK cells can recognize a range of
tumors and stress related markers without prior exposure to antigen (eg, via immunization).
NK cells play a role in cancer immunity attacking cells that down regulate MHC class I
molecules. Certain types of cancer cells down-regulate MHC class I molecules as an attempt
to evade CTLs; the abnormal clone, however, risks detection and elimination by NK cells for
reduced expression of surface MHC molecules [18].
Macrophages play a major role in cancer, exhibiting both anti-and pro-cancer behavior.
Macrophages are part of the innate immune system and can be divided into the opposing M1
and M2 type macrophages. M1 activity inhibits cell proliferation and causes tissue damage.
M2 activity promotes proliferation and repair. Tumors are capable of promoting M2 macro‐
phage phenotypes which then aid in tumor angiogenesis, immune suppression, and tumor
progression [19].
Dendritic cells (DC) are professional antigen-presenting cells and are a transitional link
between the innate and adaptive immune system, inducing and maintaining T-cell immunity.
DCs are outfitted with antigen-processing machinery (APM) allowing them to uptake and
process TAAs. Processed TAAs are then loaded on MHC class I and II and presented to the
appropriate T-cells. Thus, activated DCs are responsible for antigen specific immune responses
by promoting activation and proliferation of T-cells. DCs can be divided into 2 major groups:
plasmacytoid and classical DC. Plasmacytoid DCs play a role in antiviral immune response.
Classical DCs can be further classified based on surface marker and function e.g. Langerhans
cell in human epidermis. DCs are potential vectors for immune priming as vaccines against
cancer antigens [20].
Antibodies play an interesting role in cancer immunity. Tumor-reactive serum antibodies from
patients have long been viewed as resources for antigen detection, both in terms of vaccine
potential and as exploitable biomarkers [21]. In other cases, antibodies isolated from cancer
patients were tested for reactivity against cancer cell lines in vitro and in vivo. The antibodies
showing specificity for tumors were all germ-line encoded and most belonged to the IgM class,
binding to surface carbohydrates on malignant cells [22]. The utility of endogenous anti-tumor
antibodies has not been clearly exploited, but may play a role in vaccine scenarios [23].
3.3. The immune response
Immune system activation is classically initiated when foreign antigens are taken up by
professional APCs such as DCs, which migrate to the nearest draining lymph node. Figure 2
shows a highly diagrammatic and simplified version of this phenomenon. Protein antigens
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are processed during transit and beyond so that peptides may be loaded onto MHC Class I
and Class II molecules for surface display by the APC. Once in the lymph node, the APC
presents the antigen to the corresponding naïve T-cell to activate it. Activation of the T-cell
requires two signals: 1) presentation/display of the processed peptide to the T-cell; and 2) co-
stimulation of the T-cell by direct contact with APC surface molecules and by the secretion of
activating cytokines (interferons, IL-12, IL-15, granulocyte macrophage-colony stimulating
factor [GM-CSF], etc) by the APC. For Signal 1, the peptide displayed must fit into the peptide
binding cleft of the host’s MHC molecules and bind with sufficient affinity that the peptide-
MHC is stably presented at the APC surface. The “T-cell of destiny” will be one whose T-cell
receptor (TCR) recognizes the displayed peptide in the context of the MHC molecule. Thus,
the T-cell must be antigen-specific. For Signal 2, the APC must be sufficiently stimulated upon
and following antigen uptake that it produces co-stimulatory molecules such as CD80 and
CD86, whose receptor, CD28, awaits on the T-cells. The APC will also produce the aforemen‐
tioned stimulatory cytokines, as well, contributing to the activation of T-cells. This cell-cell
interaction, with the various presentation of antigens and ligands to receptors requires close
contact between the cells, and has been termed “the immunological synapse” [24]; for further
review, see [25].
3.3.1. Tumor evasion
Given the descriptions of the immune system cited earlier, one would think that attempts by
the immune system to eradicate tumors are a rare phenomenon. In fact, TAAs are found in the
sera of some cancer patients. Still, however, the development of many human cancers is not
blocked by the immune system. A likely explanation considers the antigenic properties of
abnormal clones; certain cancers utilize the tolerance of the immune system to self-antigens
by only expressing proteins that fly under the immunologic radar. Another possibility is
immunoevasion—strategies employed by antigenic tumors after initial insult by the immune
system.
3.3.2. Immunoevasion
The strategies of immunoevasion enable tumor cells to grow and create clinically relevant
tumors. The immune system acts as a selective force on the initial tumor, allowing abnormal
clones to escape elimination. Perhaps the most obvious evasive maneuver employed by tumor
cells is to hide their identity by ceasing to display specific TAA and TSA. By doing so, abnormal
clones evade elimination by cytotoxic T-lymphocytes. Consider a melanoma patient who was
vaccinated with tyrosinase protein expressed by his melanoma cells. Initially, his melanoma
regressed as a result of the immune response. Soon, however, tyrosinase-negative clones
emerge while the tyrosinase-positive clones continue to regress. The tyrosinase-negative
clones continue to proliferate rapidly until his death, a process called “immune escape”. A
possible explanation to the rise of the tyrosinase-negative melanoma cells is the diverse
population of abnormal clones created by faulty DNA replication in cancerous cells. The
tyrosinase-negative clone was then selected for by the immune system. This scenario is evident
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Figure 2. Antigen uptake, processing, and presentation. Pathogenic cells may lyse for a number of reasons, releasing
normal and abnormal (viral, mutated, mis-expressed) proteins or other products. Scavenging Antigen Presenting Cells
(APCs) may encounter the debris, internalize, and process it into peptides that are loaded onto MHC molecules and
presented with co-stimulation to T cells in the lymph node, activating the T cell.
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both in murine [26] and human studies [27], and is a concern where a particular antigen may
be inconsequential to tumor physiology.
Some antigens, however, are essential for the function of tumor cells and neoplastic growth.
In cancer cells that cannot down regulate TAAs, an alternative immunoevasive strategy is
employed—downregulation of MHC class I molecules by repressing MHC gene transcription,
instability of MHC at the cell surface by reduction of β2 microglobulin, or with proteasomal
or transporter associated with antigen processing (TAP) deficiencies leading to poor peptide
processing/loading [27]. Such strategy can be seen in various forms of human cancers (e.g.
lung, breast, colon, head & neck squamous cell carcinoma). Such downregulation or loss of
MHC class I expression in human cancer represents a poor prognosis. Nevertheless, downre‐
gulation of cell surface MHC class I molecules attracts the attention of Natural Killer (NK) cells.
NK cells patrol the body looking for cells that have reduced their cell surface display of MHC
molecules. Decreased level of MHC class I molecules or total loss prompts destruction of cells
by NK cells. This phenomenon explains why certain cancers block a minute fraction of surface
MHC class I molecules. Perhaps this small fraction of surface MHC molecules prevents NK
cell attack, but strategies to upregulate MHC I expression would be a consideration [28].
Another way by which abnormal clones evade NK cells is by repressing NKG2D ligands—
stress-signaling proteins displayed by cells in stressful situations such as viral infections and
neoplastic transformations. NK cells display a receptor on its surface (NKG2D) capable of
recognizing various stress signals such as MICA and MICB. Binding of the NKG2D receptor
to stress signals results in activation of NK cell’s cytotoxic response and rapid killing of cells
expressing the stress signals. Abnormal clones then can repress expression of NKG2D ligands
in various ways, such as by secretory release or shedding of NKG2DLs [29] or regulation of
expression at several levels [30]. The shedding strategy employed by human melanoma cells
allows for continued expression of stress signals such as MICA, but as decoy ligands—the
stress signals are released in surrounding medium instead of being displayed on cell surface.
This diverts the attention of NK cells and CTLs from the ligands displayed on the cells surface.
Macrophages also play a role in tumor elimination responding to several signals on the surface
of tumor cells. One protein expressed on the surface of various normal cells throughout the
body, CD47, is used to protect the cells from random attacks by macrophages. Consider the
downregulation of CD47 in erythrocytes as they progress through their life cycle. Such
downregulation ensures that older cells are discarded by macrophages. Circulating malignant
mammary cells have used CD47 to their advantage; by over-expressing CD47, they are able to
evade the innate immune system acting via macrophages [31].
Not only can tumor cells evade the attacks of the immune system, but also they can launch
counterattacks on lymphocytes. Cytotoxic lymphocytes utilize the Fas Ligand (FasL) molecule
on its surface to bind and activate Fas receptors on target cells. Activation of Fas receptors
leads to activation of the extrinsic apoptotic pathway. Cancer cells acquire resistance to the
FasL through mechanisms that are not well understood. This leads to abnormal clones that are
resistant to destruction by cytotoxic T-lymphocytes. Additionally, they also acquire the ability
to synthesize and secrete soluble forms of FasL. The secretion of FasL does not affect the already
resistant strain; however, some studies have shown that they do affect some lymphocytes
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leading to activation of extrinsic apoptotic pathway and lymphocyte death. This strategy
ensures a safe microenvironment for the growing neoplasm [32].
In addition to FasL, some human cancers have been shown to secrete TGF- β  or Interleu‐
kin-10 (IL-10). Both IL-10 and TGF- β are immunosuppressive agents secreted by normal cells
of the immune system with TGF- β being is the most potent immunosuppressive cytokine. TGF-
β has many biological effects including the inhibition of 1) APC antigen presentation; 2) APC
maturation; 3) T-cell activation and differentiation. Studies have shown that TGF- β is upregu‐
lated in glioma clones that are resistant to CTLs [33]. IL-10 on the other hand is capable of
downregulating the expression of MHC class II antigens and Type 1 T-Helper (Th1) cyto‐
kines. The expression of IL-10 in glioma tissue has been correlated with tumor grade [34, 35].
In addition to CTLs and macrophages, tumor cells have been shown to recruit regulatory T-
lymphocytes (Treg) to essentially fend off attacks by other lymphocytes. Treg cells are capable
of suppressing T-helper lymphocytes and CTLs. These may be immature T cells committed to
the regulatory lineage, or antigen-driven induced Tregs [36]. Research has shown that the
percentage of Treg cells increases by 3-5 fold in cancer patients especially in tumor infiltrating
lymphocytes (TILs). Furthermore, the degree of Treg infiltration correlates with tumor grade
[37]. The ability of tumor cells to attract Treg cells depends on the secretion of chemokine
CCL22. CCL22 acts on CCR4, a receptor on the surface of Treg cells to attract Treg cells towards
the tumor [38, 39]. While present in the tumor, Treg cells are capable of indirectly suppressing
both the humoral and cellular branch of the immune system through inactivation of T-helper
cells. The existence of Treg cells in the tumor mass questions the association between the total
number of TILs and tumor prognosis. TILs were assumed to be cytotoxic T-cells, but if a
substantial fraction of TILs are Treg cells then this notion casts a shadow of doubt over the
significance of TILs in tumors [40].
Myeloid-derived suppressor cells (MDSCs) are another cell type recruited by tumors to evade
host immune defenses. MDSCs comprise a heterogeneous group of immature myeloid cells
that play a major role in the immune suppressive tumor microenvironment (TME) [41]. As a
part of their normal physiologic role, immature myeloid cells play a role in replenishing DCs
and macrophages in early phases of trauma and stress and avoiding immune pathology in
later stages [42]. The TME, however, influences local myeloid cells to become immunosup‐
pressive [43]. Additionally, tumors initiate myelopoiesis, thus recruiting more immature
myeloid cells [44]. MDSCs play a role in tumor progression by inhibiting T-cell response and
their elimination has been shown to improve anti-tumor immunity [45]. Although treatment
aimed at MDSCs could potentially be effective, efforts at characterizing MDSCs have been
fruitless providing inadequate information to understand their phenotypical and functional
heterogeneity.
3.4. Immunology of the CNS
The ability to restrict collateral damage caused by the immune response is essential, especially
in the CNS. As a result, a status of immunological privilege is maintained in the brain limiting
the magnitude of the immune response and inflammation.
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Due to the delicate nature of the cells composing the central nervous system (CNS), the
blood brain barrier (BBB) tightly controls molecular passage and cellular migration in and
out of the CNS. The BBB is composed of both capillary and post capillary vessels. The ability
of the BBB to tightly regulate passive diffusion of hydrophilic molecules results from the se‐
lectivity of the tight junctions (TJ) between endothelial cells in the CNS vasculature [46].
Consequently, the BBB has been implicated in the regulating the immune response in the
CNS by restricting molecular access to cerebral interstitial fluid (CIF).
As discussed above, the activation of the immune response is maintained throughout the
body: APCs uptake antigen, migrate to lymphatics, appropriate T-helper cells and CTLs are
activated. However, professional antigen presenting cells (APCs) such as dendritic cells in
the systemic circulation have not been described in CNS parenchyma, but DCs are present
in vascular-rich regions of the CNS [47]. Instead, microglia are the primary resident APCs in
the CNS [48]. Microglia express MHC class II antigens and T-cell co-stimulatory molecules
giving them the ability to present antigens to T-helper cells. Once antigens are taken up by
APCs in the CNS, presentation of the antigen seems to take place in the cervical lymph no‐
des (Dunn et al., 2007). T-cells are not normally found in the brain unless activated [49], but
T-cells and antibodies do have access to the brain [50].
Migration of leukocytes towards the CNS starts with the interaction between leukocytes
attracted to chemokines and adhesion molecules on endothelial cells. The chemokines secreted
by the site of inflammation activate G protein-signaling, thus activating the leukocyte and up-
regulating integrins. Through a tight interaction involving adhesion molecules on lympho‐
cytes and endothelial cells (VCAMs, ICAMs, and LFAs), the cells transmigrate into the
parenchyma [51].
4. Neoplasia in the CNS
4.1. Glioblastoma multiforme (GBM)
Brain tumors exist as two distinct types, malignant and benign. This chapter will focus
malignant tumors originating in the brain, primarily glioblastoma multiforme (GBM). Tumors
originating from astrocytes/glial cells are named gliomas with (GBM) being the most common
and aggressive primary adult brain tumor. GBM is a grade IV astrocytoma arising from
astrocytes and is characterized by central areas of necrosis surrounded by anaplastic cells.
Median survival time is less than 15 month and significantly less for patients with recurrent
tumors [52]. GBM can present as primary or secondary tumor. Primary GBM is generally seen
in older patients as a result of EGFR overexpression, PTEN mutations, and mdm2 gene
amplification [53]. Primary GBM is thought to be a single step transformation with no clinical
background. Secondary GBM is seen in younger patients as a slow multi-step transformation
process. Secondary GBM results from p53 inactivation or overexpression of PDGF ligand,
receptor, or both [54].
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4.2. Glioma immunity vs immune suppression
A number of potential TSA and TAA have been identified in gliomas (a listing may be found
here [55]) including a number of antigens previously found in melanoma (eg, gp100, MAGE-1
and-3, MART-1, NY-ESO-1, tyrosinase and related proteins 1 and 2). Others include tenascin-
C, IL13Rα2, EphA2, and EGFRvIII. Whole proteins or peptides derived from these antigens
could be used in vaccine scenarios with a goal of providing antigen to APCs (presumably DCs),
usually in the context of an adjuvant or immune stimulant to promote antigen uptake and
activation of the DCs. Alternatively, the DCs may be harvested as progenitors from patients,
differentiated and bulk-proliferated ex vivo, supplied with antigen, and then returned to the
patient as a cellular vaccine. In other scenarios, lysates or particular proteins that may “sample”
the antigenic peptide repertoire of the tumor (eg, heat shock proteins or chaperone proteins)
[56, 57] may be employed to provide “blanket” immunogenicity by theoretically supplying all
antigens rather than selected ones.
Unfortunately, gliomas are capable of employing some or all of the immunoevasive strategies
discussed above. Patients with malignant gliomas often have weak adaptive immune systems
due to the increased percentage of Tregs [58, 59]. In addition, malignant gliomas have been
shown to secrete TGF-β and VEGF capable of direct immune suppression as well as inducing
myeloid-derived suppressor cells [60]. VEGF has been shown to inhibit NF-κB signaling in
hematopoietic progenitor cells, thus inhibiting dendritic cell maturation.
4.3. Current therapies
Available therapies for GBM and other brain tumors include chemotherapy, fractionated
radiotherapy, and image-guided tumor resection. Current chemotherapeutic options for
glioblastoma include Gliadel wafers (carmustine/BCNU), cisplatin, and temozolomide (the
drug that is part of the standard of care regimen concurrent with radiation, and then in the
adjuvant setting [52].
Carmustine is an alkylating agent and was the first drug approved for the treatment of GBM.
Carmustine inhibits cancer growth via alkylation of O6-guanine position on DNA and thus
crosslinking the helix. Carmustine has shown modest improvement in patient survival in early
trials (reviewed here [61]) and has been the cornerstone of GBM adjuvant therapy. Although
carmustine can cross the blood brain barrier (BBB), delivery to target site is difficult. Addi‐
tionally, carmustine effectiveness hindered by its short half-life, systemic toxicity and tendency
for chemo-resistance.
For better delivery of carmustine to action site, Gliadel wafers are used. Gliadel wafers are
made of carmustine-loaded biodegradable polymers placed in the resection cavity formerly
occupied by the tumor post-surgical excision. As the polymer is degraded, carmustine is slowly
released. A study conducted by Westphal et al. in 2003 [62] showed that Gliadel-treated
patients had a median survival rate of 13.9 month compared to 11.6 month in placebo controls.
The complications of Gliadel wafers are serious and life threatening--seizures, edema, and
hydrocephalus [63, 64].
The current standard of care for GBMs is maximal surgical resection followed by concurrent
fractionated radiation and temozolomide (TMZ), with TMZ then given in the adjuvant setting
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[52]. There are variations on this theme, including the addition of the anti-VEGFA antibody
bevacizumab (as a form of anti-angiogenesis), but surgery, radiation, and TMZ are the staples
[65]. TMZ is an oral DNA alkylating agent capable of crossing the BBB and inducing apoptosis
[66, 67]. Attempts at combination treatments using TMZ and other chemotherapy drugs have
shown little or no benefit when compared to TMZ alone [68]. TMZ efficacy varies, however,
in patients depending on the action of the enzyme repairing the lesion produced by the drug,
O6 methyl guanine DNA methyl transferase (MGMT) [69].
Cisplatin is a cis platinum complex containing 2 chloride and 2 amine groups. Once in the
body, cisplatin triggers apoptosis by crosslinking DNA. Cisplatin’s efficacy on brain tumors
has shown few benefits. A phase 3 trial showed no significant outcome improvement in
patients administered carmustine and radiation therapy versus cisplatin, carmustine, and
radiation therapy [70].
4.3.1. Understanding Glioma-Associated Antigens (GAAs)
Considering the low median survival time, current therapies are inadequate and there is a
strong need for novel therapies with superior safety and efficacy. In order to develop new
therapies, it’s important to be familiar with potential glioma-specific molecular targets. In light
of the potential utility of immunotherapy as a novel therapeutic strategy for patients with
GBM, this section will discuss Glioma-Associated Antigens (GAA), some of which were briefly
mentioned above.
IL13Rα2
IL13Rα2 is a glycoprotein overexpressed on the surface of many glioma cells. The only other
normal tissue where IL13Rα2 can be found is in the testes; therefore it represents a great
potential target for glioma therapy [71].
EphA2
A receptor tyrosine kinase overexpressed on the plasma membrane of gliomas and tumor-
associated vasculature. EphA2 is thought to play a role in developmental processes and
carcinogenesis. EphA2 has been shown to provoke a response from cytotoxic T-lymphocytes
against glioma clones [72].
EGFRvIII
Type III variant mutation of EGFR (EGFRvIII) is seen with patients with primary and recurrent
GBM and is currently the most prevalent TSA found on glioma. EGFRvIII promotes and
enhances carcinogenesis [73]; EGFRvIII encodes a constitutively active tyrosine kinase that
does not need to dimerize nor bind ligand for activity [74, 75].
Survivin
Although not specific for gliomas, survivin belongs to the inhibitor-of-apoptosis protein family
that is overexpressed in the majority of human cancers [76]. It is considered a marker of poorer
prognosis in patients with GBM [77].




Wilm’s Tumor 1 (WT1) is a transcription factor that is important in the developmental biology
of many organs; its mis-expression may drive epithelial-to-mesenchymal transitions prevalent
in many cancers [78]. WT1 is overexpressed in solid tumors, leukemias, and gliomas [79]. WT1
has both oncogenic and tumor suppressor capacities depending on mutational status, over‐
expression, and tissue source [80]. It is considered to be a viable tumor antigen with multiple
applications [81].
SOX
Sry-related high mobility group box (SOX) is a family of transcription factors involved in
directing the development of various tumors and cell types [82]. SOX2, SOX5, SOX6, and SOX11
are preferentially overexpressed in tumors of the CNS [83] and in glioma stem cell lines [84].
5. Immunotherapy
Understanding how cancer escapes the immune system provides clues for researchers and
clinicians to intervene at critical points and empower the immune system. Although the field
of cancer immunotherapy has much to prove, it has the potential to treat various forms of
cancer with high specificity and relatively low toxicities. The superior therapeutic specificity
in particular makes immunotherapy an attractive, tolerable alternative or possible adjuvant to
chemotherapy for patients. Available cancer immunotherapeutic options include vaccines,
monoclonal antibodies, adoptive cell therapy (ACT), and cytokine therapy, and the so-called
“checkpoint blockades”.
5.1. Glioma vaccines
Vaccines harness the immune system and allow it to target glioma-associated antigens via the
processes of antigen provision/uptake to APCs, followed by the stimulation of specific
lymphocytes by the APCs. The field of antitumor vaccines is one of the most studied and
established modalities of immunotherapy. There are 3 general types of glioma vaccines: whole
cell/tumor lysate vaccines, peptide-based vaccines, and dendritic cell vaccines. These vaccines
may be used with various adjuvants or immune stimulants; they may be used amidst the
standard of care; they may involve additional immune stimulation or regulatory suppression
strategies.
Whole cell glioma vaccines involve administration of irradiated allogeneic or autologous
glioma cells providing multiple GAA for the immune system to target. Obviously, autologous
whole cell vaccines would provide the most personalized treatment using GAAs specific to
each patient. On the other hand, such tumor cells may also provide tumor suppressive entities
[85]. Manufacturing whole cell vaccines, however, is a very demanding task especially when
handling large-scale glioma cell cultures, and when time is of the essence for patients with
short times to progression [86]. Additionally, this approach puts patients at a theoretical risk
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for autoimmune encephalomyelitis [87]. However, several autologous cell vaccine trials by
Schneider et al among others have reported no major adverse effects [88].
An alternative to whole cell glioma vaccine and their associated autoimmunity risks are
peptide-based vaccines. Peptide-based vaccines use synthetic peptides based on shared GAA
epitopes. Unlike whole cell glioma vaccines, peptide-based vaccines target one or few GAAs
specific to each patient’s tumor. This may be beneficial in generating higher levels of specific
responses to a particular antigen; it may also provide an easier outlet for immune escape by
antigen loss. However, this strategy does present a lower risk for development of autoim‐
munity, and peptide manufacturing is relatively simple compared to handling large-scale
glioma cell cultures. Peptide-based vaccines targeting EGFRvIII have been shown to be safe
and potentially beneficial in the ACTIVATE (A Complementary Trial of an Immuno-therapy
Vaccine Against Tumor-Specific EGFRvIII) series of trials (including ACT II, ACT III, ACT IV,
ReACT [89, 90]). The ACTIVATE phase II trial recruited 18 patients with EGFRvIII expressing
tumors that received CDX-110 (14-amino acid EGFRvIII epitope conjugated to a keyhole limpet
hemocyanin as a hapten carrier with GM-CSF as an adjuvant) along with standard radio-and
chemotherapy. The median time to progression was 14.2 month and median survival was 26
month; no adverse events were recorded. ACT IV is a phase III trial comparing vaccine/GM-
CSF+TMZ vs TMZ and placebo alone (see Table 1).
A somewhat different version of peptide-based therapy is that of chaperone protein or “heat
shock protein” (HSP)-based vaccines [56, 57]. The concept here is that chaperone/HSPs bind
intracellular peptides as part of their chaperone duties. Thus, purification of particular
chaperone/HSPs from tumor cells results in a population of peptides that are specific to that
particular tumor, even though the chaperone/HSPs may appear identical. Upon vaccination,
this would provide APCs with a “peptide fingerprint” of the tumor, making the vaccine tumor
—and patient—specific, even if the chaperone proteins were ubiquitous in different cell types
(see Figure 3). The current chaperone protein vaccine in use for GBMs is variously called
Prophage, Oncophase, and HSPPC-96; the protein purified from tumors for vaccine generation
is glucose-regulated protein (GRP) 94, also called glycoprotein (gp) 96.
A key common feature of most peptide-based vaccines is the inclusion of immune stimulatory
factors as adjuvants (eg, DNA constructs such as polyICLC [91], GM-CSF [92], Freund’s
adjuvant [93], TLR agonists [94], and cytokines [95]). This is necessary because the lack of APC
stimulation will result in poor activation of T cells, with possible conversion to an anergic state.
The chaperone/HSP vaccines utilize the “danger signal” effects of extracellular HSPs as innate
immune stimulators to essentially provide their own adjuvanticity [96]. An advantage of
peptide antigens of known sequence is that provides investigators with a means of immune
monitoring by measuring and tracking the immune response, by T cell readouts [97] and
sometimes by antibody responses [23]. One question that remains is whether results from
immune monitoring yield true prognostic information, as often there is a positive correlation
with immune measures of vaccination, but these do not necessarily appear related to clinical
benefit [98].
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Trial Name Phase n Therapy Primary Outcome Trial Identifier
Vaccine therapy +
sargramostim I 9
ISA-51/survivin peptide vaccine +
sargramostim Safety NCT01250470
HSPPC-96 vaccine +
Temozolamide II 55 HSPPC-96 + Temozolamide Safety NCT00905060
ACT III II 82 CDX-110 1 TMZ 1 RT Progression-freesurvival NCT00458601
ACT IV III 440 CDX-110 1 TMZ Overall survival NCT01480479
Table 1. Summary of ongoing peptide-based vaccine trials for malignant glioma. Data obtained from National
Institutes of Health. Information is available by Trial Identifier at http://www.clinicaltrials.gov.
5.2. Antibodies
Antibodies are utilized in cancer immunotherapy usually as human, humanized, or mouse-
human chimeric monoclonal antibodies (mAb) that target tumor-associated antigens (TAA)
and tumor-specific antigens (TSA), generally on the surfaces of cancer cells, or targeted against
secretory molecules. There are 2 categories of mAbs most frequently used: naked and conju‐
gated antibodies. Naked antibodies work independently without an attached radiolabel or
toxin. Once bound to the target cell, naked antibodies mark cells to be eliminated by the
immune system, usually neutrophils and macrophage. If such mAbs target surface receptors,
they may interfere with ligand binding or downstream function. Conjugated or “armed”
Figure 3. Chaperone/Heat Shock Protein (HSP) vaccines from tumors. Various HSPs have been shown to be immuno‐
genic when purified from tumors. However, purification of the same HSPs from different tumors does not generate
cross-protection (eg, if HSPs are purified from Tumor X and used as a vaccine, but the host is challenged with Tumor
Y, there will be no anti-tumor protection, because the antigenic peptide repertoire differs between the two tumors,
even if the HSPs appear the same).
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antibodies, on the other hand, are mAbs joined to a toxin, chemotherapy drug or a radioactive
particle. Conjugated antibodies are essentially vehicles specific for targeting abnormal clones,
sparing normal cells from toxic therapy. Regardless of the type, it is crucial that the mAb bind
with high affinity and specificity to target [99]. Monoclonal antibody therapy has been
successful in treating lymphomas (rituximab), breast cancer (trastuzumab), and more recently,
recurrent glioblastoma (bevacizumab). Malignant gliomas are vascular tumors producing
vascular endothelial growth factor (VEGF), which promotes angiogenesis and tumor progres‐
sion. Bevacizumab is a humanized monoclonal antibody against VEGFA administered in
combination with chemotherapy [100]. Inhibition of VEGF via bevacizumab followed by
cytotoxic chemotherapy and radiation therapy has generated encouraging results in several
studies [100].
The use of mAbs to treat GBM has been investigated in preclinical systems. Y10, anti-EGFRvIII
naked murine IgG2a, significantly increased survival time in mice bearing EGFRvIII express‐
ing tumors by an average of 286% [101]. Additionally, Y10 was shown to inhibit cell prolifer‐
ation and DNA synthesis in vitro by complement activation and antibody dependent cell-
mediated cytotoxicity (ADCC). Another type of anti-EGFRvIII (or “delta 2-7”) is mAb 806,
which has also shown pre-clinical efficacy against EGFR-amplified tumors [102] and has
shown good targeting capability and pharmacokinetics in a phase I study [103]. Anti-EGFRvIII
mAbs such as L8A4 (murine IgG1) have also been radiolabeled and utilized in pre-clinical
testing [104], including boronation [105].
Given the role of EGFR in the progression of malignant glioma, efforts to inhibit EGFR have
culminated in phase I study conducted by Faillot et al which demonstrated the ability of murine
anti-EGFR mAb EMD55900 to bind the tumor in vivo and is well tolerated in patients [106].
Repeated infusions only resulted in one patient developing human anti-mouse antibodies
(HAMA response). Despite the substantial binding of EMD55900 to targets, phase I/II clinical
trials using EMD55900 administered intravenously showed no significant tumor regression
[107]. The use of another anti-EGFR antibody (chimeric humanized), cetuximab, showed good
tolerability but limited efficacy in patients with recurrent GBMs [108]. A recently-developed
chimeric humanized anti-EGFR antibody, nimotuzumab, is in clinical trials for malignant
gliomas, but the studies are not mature enough to provide much information [109].
5.3. DC Immunotherapy
The  superior  antigen  presenting  ability  of  DCs  has  been  harnessed  in  novel  cancer
vaccination strategies. DC vaccines take advantage of the antigen presenting machinery of
these cells  to activate CD4+ and CD8+ T cells  that  are specific  for  TAAs/TSAs.  DCs are
generated using autologous peripheral  blood leukocytes that are incubated with specific
cytokines to induce differentiation of monocytes into DCs; the type of cytokine used dictates
the quality of DCs generated e.g. GM-CSF and IFNα generate DCs highly potent in T-cell
activation. DCs are then pulsed with 1) synthetic tumor antigens (TAAs) or 2) autologous
tumor lysate, or 3) tumor RNAs to promote activation and antigen presentation, and are
injected back into the patient [110].
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Phase I trials assessing safety have been carried out by Yu et al. in 7 patients (+2 with anaplastic
astrocytomas) who received injections of autologous glioma peptide pulsed-DCs; these
peptides were acid-eluted from tumor cell surfaces (presumably from MHC molecules). Four
out of 7 patients developed tumor specific T cell cytotoxicity, and others had T cell infiltrates
into their tumors at reoperation [111]. The Cedar Sinai experience in DC vaccine clinical trials
is discussed here [112]. In another phase I trial done by Liau et al., 12 patients were adminis‐
tered DCs also pulsed with autologous glioma-eluted peptides from surface of resected
tumors. Fifty percent of the patients showed increased systemic and intracranial immunologic
responses while reporting no adverse effects from vaccination [113]. More recent studies by
that group have utilized autologous tumor lysate as the antigen source due to its availability
from surgical resection, whereas the use of specific GAAs requires patients to express suitable
MHC molecules able to present the GAA [114]. Prins et al have also conducted a phase I trial
using TLR7 agonists (imiquimod or polyICLC) combined with autologous tumor lysate-
pulsed DC vaccination. Twenty-three GBM patients were enrolled showing a mean overall
survival of 31 months and 47% 3-year survival [115]. The use of DC vaccines pulsed with
tumor-derived RNAs (total polyA+RNAs or specific mRNAs) was demonstrated almost 20
years ago [116], and this strategy has made it to clinical trials for patients with GBMs [117]. An
advantage of RNA as a source of antigen is that it can be prepared by standard conditions, or
synthesized cheaply.
DC-based vaccine trials have been prevalent in neuro-oncology, and many of those are
reviewed here [110], along with a listing of current DC vaccine trials in glioma (Table 2).
Trial Name Phase n Therapy Primary Outcome Identifier
ATTAC I 16 CMV pp65-LAMP mRNA-loadedDCs Safety NCT00639639
NY-ESO-1
intranodal vaccine I 30
DEC-205-NY-ESO-1 fusion protein
+ sirolimus Safety NCT01522820
Vaccine therapy for
recurrent GBM I 50 BTSC mRNA-loaded DCs Safety NCT00890032
Phase I study of










ICT-107 IIb 200 TAA Overall survival NCT01280552
DCVax-L III 300 Autologous tumor cell lysate Progression-freesurvival NCT0045968
Table 2. Summary of ongoing DC vaccine clinical trials for malignant glioma. Data obtained from National Institutes
of Health. Available at http://www.clinicaltrials.gov.
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5.4. Adoptive Cell Therapy (ACT)
ACT is the manipulation of autologous cells ex vivo to be infused back into the patient. ACT
aims to amplify cell lines that best fight cancer including 1) TILs 2) peripheral blood mono‐
nuclear cells (PBMCs) 3) lymphokine-activated killer cells (LAKs) and 4) antigen specific CTLs.
ACT originated as a way to restore viral immunity in patients undergoing hematopoietic stem
cell transplant and to prevent cytomegalovirus (CMV) reactivation in transplant patients. Early
use of adoptive cell transfer to treat non-viral malignancies was seen in attempts to treat
hematologic malignancies and melanoma. Steinbok et al. was the first to demonstrate the
possibility of ACT in treatment of gliomas in 1984 [118]. Steinbok collected autologous PBMCs
to be re-infused into the cavity created post tumor excision. The study, however, showed no
significant beneficial outcomes. Newer technologies and a better understanding of the cells
involved have made ACT an attractive approach. However, the ex vivo generation of large
quantities of specifically reacting cells is cumbersome, expensive, and not necessarily available
everywhere.
5.4.1. Cytotoxic T-Lymphocytes
Based on the findings that CTLs can bypass the BBB and migrate into brain parenchyma
(reviewed here [119]. GAA-reactive CTLs isolated from peripheral blood and glioma tissue
might mount a favorable antitumor response in glioma patients. Glioma tissues are infiltrated
with GAA-specific CTLs that could be expanded ex-vivo using IL-2 and subsequently selected
for antigen specificity [120]. Once GAA-specific CTLs have been isolated, ex-vivo manipula‐
tions include cloning high affinity TCRs, expression of chimeric antigen receptors (CARs), and
T-cell subtype selection. Cloning high affinity TCRs is done by isolating CD8+T cells with high
GAA affinity for particular antigens and cloning TCR α and βgenes to be exogenously induced
in bulk CD8+cells. ACT using high affinity TCR T-cells has resulted in regression of metastatic
melanoma [121], suggesting the potential of applying this method to glioma therapy. ACT of
various types using CTLs has a history in glioma trial therapy, but none have shown consistent
benefit [122].
Chimeric Antigen Receptors (CARs) are chimeric molecules composed of epitope-binding
domain of mAb fused to CD3 signal transduction domain (Gross et al., 1989). CAR is an
alternative to transgenic high-affinity TCRs and don’t require the expression of MHC mole‐
cules. CAR-T cells have just reached clinical trial stage in GBMs (NCT02209376 at ClinicalTri‐
als.gov) targeting EGFRvIII. Other targets include IL13Rα2 [123], HER2/Neu (EGFR2) [124],
and 3rd generation anti-EGFRvIII cells [125].
5.4.2. LAK cells
Lymphokine-Activated Killer (LAK) cells are activated prior to exposure to IL-2 in vitro. LAK
cells possess cytotoxic machinery capable of lysing abnormal clones (allogeneic and autolo‐
gous) sparing normal cells. As a result of the toxic systemic effect of IL-2 administration, in
vivo human trials using LAK cells are limited and researchers have resorted to ex vivo LAK
trials, with an occasional long-term survivor [126]. Administration of LAK cells into post
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excision cavity combined with IL-2 therapy has shown to increase median survival from 26
weeks to 53 weeks in patients with recurrent GBM [127]. LAK cells, however, have limited
specificity to tumors in vivo and their tumor recognition mechanisms are not well understood.
5.4.3. Lymphodepletion
Lymphodepletion is the process killing white blood cells to enhance adoptive transfer therapy
possibly in vaccination scenarios. Lymphodepletion induces homeostatic proliferation, a
situation where lymphocytes proliferate in an enriched cytokine environment and with
lowered thresholds of stimulation and decreased numbers of Tregs [128]. Lymphodepletion
has a long history in the ACT therapies in melanoma, where there have been objective response
rates of greater than 50% [129]. There is also a suggestion that the lymphopenia induced by
TMZ chemotherapy may actually benefit anti-tumor vaccination by driving homeostatic
proliferation [130], and this may aid in Treg depletion by mAb blockade [131]. Dose-dense
TMZ regimens may induce more myelotoxicity, however [132].
6. Virotherapy
Oncolytic virotherapy is the use of genetically engineered viruses for the treatment of malig‐
nancies. Oncolytic viruses are engineered to specifically infect malignant cells, thus sparing
the normal tissue surrounding the tumor [133]. The intracellular replication of the oncolytic
virus then results in cancer cell lysis and release of viral progeny that infects additional
cancerous cells [134]. The use of oncolytic viruses for GBM treatment has been tested in clinical
trials for the last 15 years with multiple phase I trials completed and some ongoing, proving
to be a safe option. Two treatment strategies exist in virotherapy 1) replication-incompetent
viruses and 2) replication-competent viruses. Replication-incompetent viruses exert their
therapeutic effect through the delivery of transgenes that exert their effect through multiple
mechanisms, one of which is discussed below [133]. Replication-competent viruses exert their
therapeutic effect via replication and lysis of target tumor cells [133].
Concerns about uncontrolled viral infection in hosts led researchers to use replication-
incompetent viruses for initial attempts in oncolytic virus therapies. Replication-incompetent
adenoviruses and retroviruses are then engineered with the herpes simplex virus thymidine
kinase gene (HSV-TK), which produces a cytotoxic metabolite from the drug ganciclovir [135].
Ram et al. used a replication-incompetent retrovirus engineered with HSV-TK for the first
phase I clinical trial [136]. Fifteen patients received viral injections to the tumor site and oral
gancyclovir with no adverse effects. Median survival time was 8.1 month; however, the lack
of statistical significance in phase III trials [137] led researchers to study replication-competent
oncolytic viruses (OVs).
OVs are attenuated viruses capable of lysing target tumor cells and activation of the local
immune response to tumor antigen release [138]. There currently exist 4 different OVs used in
published clinical trials. Herpes Simplex Virus G207 is among the OVs used in clinical trials.
G207 is unable to replicate in normal cells because it lacks ribonucleotide reductase. In the first
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of 2 separate phase I clinical trials, of the 21 patients injected with G207, 8 patients demon‐
strated reduction in tumor size shown on MRI scans [139]. In the second trial, investigators
demonstrated successful replication of the virus in the tumor [140]. Although safe, OVs tested
to date have proven less efficacious than expected. However, there are efforts to create new
viruses equipped with cytotoxic agents and other viruses specifically targeting the stem cell
population of GBM [141, 142]. There are also studies showing safety testing of a polio virus-
rhino virus chimera that shows high targeting capacities for tumors (due to overexpression of
the poliovirus receptor NECL5) and replication within tumor cells due to putative biochemical
abnormalities [143, 144]. There is a newly-opened trial based on this virus (NCT01491893 at
ClinicalTrials.gov). Other clinical trials involving viral therapy are listed in Table 3.




I Carcinoembryonic antigen-expressing 40
Safety, MTD, viral propagation
and expression NCT00390299
NDV-HUJ in




I Mutation in E1A and RGD-related integrin expression 31
No. of patients with adverse
events NCT01956734
Table 3. Selected ongoing oncolytic viral clinical trials for malignant glioma. Data obtained from National Institute of
Health. Available at http://www.clinicaltrials.gov.
7. Immune checkpoint blockade
As mentioned above, certain molecules expressed on T cells, with ligands or counter receptors
expressed on tumors or Tregs, may provide an avenue of control over maintenance of an
activated T cell status or denial of a suppressive effect. One such T cell surface molecule is
cytotoxic T lymphocyte antigen 4 (CTLA4), which is a receptor that downregulates T cell
activity by binding to CD80 and/or CD86 on other T cells, particularly Tregs. Ipilimumab is an
antibody that binds to CTLA4 and prevents its binding to CD80/86, thus maintaining the
activated state of the T cell (and running some risk for autoimmunity) [145]. This antibody is
approved for the treatment of therapy-resistant metastatic melanoma [146], and has been in
clinical trials for patients with brain metastases [146]. There is currently a clinical trial open for
patients with recurrent GBM utilizing this drug (NCT02017717, at ClinicalTrials.gov) as well
as the anti-PD-1 antibody nivolumab (below).
PD-1 and PD-1L/PD-2L are another pair of T cell inhibitory receptors/ligands. The ligands
PD-1L or PD-2L are often upregulated on cancer cells, where engagement with PD1 on T cells
leads to T cell apoptosis [147]. Nivolumab is an antibody directed against PD-1 that prevents
interaction with surface ligands on other cells, thus preventing the immune suppression
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induced by the tumor [147]. As mentioned, this antibody is used along with ipilimumab as
checkpoint blockades in a clinical trial for patients with recurrent gliomas.
8. Conclusion
Glioblastoma Multiforme (GBM) remains the most common CNS malignancy with abysmal
prognosis. Our current GBM therapies are clearly inadequate stressing the need for new
treatment modalities. Immunotherapy is an emerging cancer treatment, potentially utilized
alongside surgery, radiation, and chemotherapy. The dynamic interactions within the tumor
microenvironment dictate the balance between tumor elimination and escape. Additionally,
high-grade gliomas employ a multitude of strategies to evade the immune system. Early trials,
however, using anti-tumor vaccines and adoptive cell therapy have demonstrated the potential
anti-tumor efficacy and feasibility of such approaches. Moreover, several promising phase III
trials are underway, and continual research provides more information and more data that
indicate immunotherapy is a viable option for the treatment of patients with these devastating
diseases.
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